《阿斯利康AstraZeneca（AZN）2024年年度報告「LSE」（英文版）（248頁）.pdf》由會員分享，可在線閱讀，更多相關《阿斯利康AstraZeneca（AZN）2024年年度報告「LSE」（英文版）（248頁）.pdf（248頁珍藏版）》請在三個皮匠報告上搜索。

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2024 What science can doWe are a global,science-led,patient-focused pharmaceutical business,committed to excellence in the research,development and commercialisation of prescription medicines.We aim to transform the lives of pati

2、ents with improved outcomes and a better quality of life.Our SupplementsDetailed information on our Development Pipeline,Patent Expiries of Key Marketed Products and Risk.See our website, sustainability reportingOur sustainability reporting is prepared in line with the UK Companies Act 2006,sections

3、 414CA and 414CB.In anticipation of the EU Corporate Sustainability Reporting Directive(CSRD),we have started to incorporate selected disclosures in this Annual Report.Our key topics covered include material sustainability topics,which have been identified through our double materiality assessment,s

4、ee page 60 for more information.Front cover image:Oncology research and development(R&D)strategy.In Oncology R&D,we have a breadth of scientific platforms to attack cancer from multiple angles,and we are harnessing the power of combinations to drive even deeper responses and bring potential for cure

5、 to more patients.Use of terms:In this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.WelcomeStrategic ReportChairs Statement 2Chief Executive Officers Review 3What science can do 5AstraZeneca at a Glance

6、 6Healthcare in a Changing World 7Our Purpose,Values and Business Model 10Our Strategy and Key Performance Indicators 12Therapy Area Review 16Business Review 32Disclosure Statements 59Risk Overview 64Financial Review 67Financial StatementsPreparation of the Financial Statements and Directors Respons

7、ibilities 138Directors Annual Report on Internal Controls over Financial Reporting 138Independent Auditors Report 139Consolidated Statements 148Group Accounting Policies 152Notes to the Group Financial Statements 160Group Subsidiaries and Holdings 214Company Statements 219Company Accounting Policies

8、 221Notes to the Company Financial Statements 223Group Financial Record 226Corporate GovernanceChairs Introduction 86Corporate Governance Overview 87Board of Directors 88Senior Executive Team(SET)90Corporate Governance Report 91Nomination and Governance Committee Report 100Science Committee Report 1

9、02Sustainability Committee Report 103Audit Committee Report 104Directors Remuneration Report 112Additional InformationShareholder information 228Directors Report 230Sustainability supplementary information 233Trade Marks 239Glossary 240Cautionary statement regarding forward-looking statements 244Con

10、tentsKey For more information within this Annual Report.For more information,see .BV Denotes sustainability information independently assured by Bureau Veritas.Material sustainability metric,is independently assured by Bureau Veritas,see definitions from page 234.Total Revenue1Up 18%at actual rate o

11、f exchange to$54,073 million(up 21%at CER),comprising Product Sales of$50,938 million(up 16%;19%at CER),Alliance Revenue of$2,212 million(up 55%;55%at CER)and Collaboration Revenue of$923 million(up 56%;54%at CER)Net cash inflow from operating activitiesUp 15%at actual rate of exchange to$11,861 mil

12、lion 202420232022$45,811m$44,351m$54,073m$54.1bn$54.1bn$11,861m$10,345m$9,808m202420232022$11.9bn$11.9bnReported Operating profitUp 22%at actual rate of exchange to$10,003 million(up 32%at CER)Core Operating profitUp 16%at actual rate of exchange to$16,928 million(up 22%at CER)$10,003m$8,193m$3,757m

13、202420232022$10.0bn$10.0bn$16.9bn$16.9bn$16,928m$14,534m$13,350m202420232022Reported EPSUp 18%at actual rate of exchange to$4.54(up 29%at CER)Core EPSUp 13%at actual rate of exchange to$8.21(up 19%at CER)$4.54$3.84$2.12202420232022$4.54$4.54$8.21$7.26$6.66202420232022$8.21$8.211 As detailed from pag

14、e 152,Total Revenue consists of Product Sales,Alliance Revenue and Collaboration Revenue.Denotes a scale break.Throughout this Annual Report,all bar chart scales start from zero.We use a scale break where charts of a different magnitude,but the same unit of measurement,are presented alongside each o

15、ther.For more information in relation to the inclusion of Reported performance,Core financial measures and constant exchange rate(CER)growth rates as used in this Annual Report,see the Financial Review from page 67 and for more information on the reconciliation between Reported and Core performance,

16、see the Reconciliation of Reported results to Core results in the Financial Review on page 72.Financial highlights1AstraZeneca Annual Report&Form 20-F Information 2024Corporate GovernanceAdditional InformationFinancial StatementsStrategic ReportContents$3.10Full-year dividend of$3.10 per share(2023:

17、$2.90)“2025 marks the beginning of an unprecedented,catalyst-rich period for AstraZeneca,an important step on our Ambition 2030 journey.”It starts with our science,and is a powerful vindication of the value of innovation.It is also a source of great pride,as it holds the hope of improving care for m

18、illions of people.Likewise,what we are doing resonates with the stakeholders I speak to healthcare professionals,patient advocacy groups,policymakers and investors.Whatever their perspective,they want to see us succeed and deliver the value of better health for people,society and the planet.A world

19、in fluxGeopolitical shifts,crises and conflict are changing the world around us.They interact with economic,demographic,societal,environmental and technological transformations,constantly changing the conditions in which we operate.Business cannot hope to predict every event or outcome but we can st

20、rengthen,through active risk management,our capabilities to absorb shocks and adapt our operations.Appropriate risk management enables us to continue implementing our overall strategy to achieve growth,drive innovation and reach more patients.We are,for example,seeing a more economically diverse lan

21、dscape with the rise of key emerging markets and a relative decline of economic concentration in the West.In addition,governments are increasingly focused on strategic autonomy,driven by concern over national security,crisis preparedness,economic competitiveness and sovereignty in key sectors.There

22、is also strong pressure to build resilient supply chains,particularly in response to climate change.Such trends are interlinked,presenting challenges and risks we need to mitigate.But they also present opportunities for growth and innovation.A strategic approach to healthcareGiven the well-evidenced

23、 societal and economic benefits,we believe governments must prioritise investment in Health and develop sustainable financing solutions.This requires public and private sectors to collaborate to ensure healthcare investments are strategic and targeted to maximise positive impact,transform service de

24、livery and generate long-term savings for health systems.By prioritising investment in screening and treating disease early,by keeping people healthy,out of hospital and economically productive,we can reduce healthcare costs.At the same time,investing in more climate-resilient,net-zero health system

25、s can help build a more sustainable and equitable future.And,eventually,it will considerably improve health equity and leave nobody behind.Finally,strengthening health systems will help them be more resilient,ensuring they are prepared for future crises and able to adapt to changing needs.Global col

26、laborations like the Partnership for Health System Sustainability and Resilience(PHSSR)are driving this transformation.AstraZeneca is a founding member of the PHSSR,now active in more than 30 countries,which commissions independent research and develops evidence-based policy recommendations for chan

27、ge.Outlook2025 marks the beginning of an unprecedented,catalyst-rich period for AstraZeneca,an important step on our Ambition 2030 journey.We are also investing in and making significant progress with transformative technologies that have the potential to drive our growth well beyond 2030.Michel Dem

28、arChairFrom my perspective,as AstraZenecas Chair,I have once again witnessed first-hand the impact we are making for patients and communities across the globe.We are making a real difference.PerformanceAstraZeneca sustained strong momentum in 2024,with Total Revenue up 18%(21%at CER)and Reported EPS

29、 up 18%(29%at CER).Core EPS was up 13%(19%at CER).Following the announcement at our Annual General Meeting in April,the Board has declared a second interim dividend of$2.10 per share,making a total dividend declared for the full year of$3.10 per share.The increase,of 7%,over 2023 underscores our con

30、fidence in future growth.A dedicated teamOf course,every global company is from time to time exposed to difficulties and 2024 was no different for AstraZeneca,as we navigated some challenging geopolitical circumstances.These included investigations by the Chinese authorities,with whom we continue to

31、 cooperate fully.However,it is in times such as these that we can really appreciate the team ethos and dedication of our people and the Board to deliver for patients.On behalf of the Directors,I extend my thanks to Pascal,the Senior Executive Team and everyone for the contributions they made to our

32、success.Strategic ambitionAt our Investor Day,we set out our Ambition 2030,an exercise in which the Board was deeply involved and supportive,and which demonstrates the trust in our pipeline.AstraZeneca has ambitious plans and is working in collaboration for healthier people,society and the planet.2A

33、straZeneca Annual Report&Form 20-F Information 2024Strategic ReportChairs Statement$54.1bnTotal Revenue(2023:$45.8bn)74Regulatory events submissions or approvals in major markets“By 2030,we aim to launch at least 20 new medicines and achieve$80 billion in Total Revenue,with sustained growth thereaft

34、er.”against our 2030 target.Our science was selected for plenary sessions at the annual meeting of the American Society of Clinical Oncology,for the sixth year running,as well as a remarkable five Presidential Plenary sessions at lung cancer and European oncology congresses.We also continued to move

35、 earlier in the treatment of disease,where there is greatest chance of success,and stepped up efforts to improve patient outcomes by harnessing the power of combinations,not only in oncology but prospectively in weight management,as well as through patient-friendly devices and formulations.Our focus

36、 on patients is demonstrated by Airsupra,where the readout from the BATURA trial both showed overwhelming efficacy in treating asthma but importantly was the first pivotal study to eliminate all in-person clinic visits.Growing and leadingWe delivered a very strong performance in 2024,with Total Reve

37、nue increasing to$54.1 billion.In our therapy areas,Total Revenue for Oncology increased 21%(24%at CER),Cardiovascular,Renal&Metabolism by 18%(20%at CER),Respiratory&Immunology by 23%(25%at CER),Vaccines&Immune Therapies by 8%(8%at CER)and Rare Disease grew by 13%(16%at CER).In our regions,Total Rev

38、enue increased by 22%in the US,14%(22%at CER)in Emerging Markets and by 27%(26%at CER)in Europe.Total Revenue decreased by 2%(increased by 3%at CER)in Established RoW.In 2024,the US represented 43%of Total Revenue.Across the world,our therapy area leadership is reflected in the fact that,for the fir

39、st time,we are the number one pharmaceutical company across our 2024 was a truly memorable year for AstraZeneca.First,it was yet another year in which we advanced our high-quality pipeline,successfully delivered medicines to millions of patients and further increased our contribution to society and

40、the planet.Secondly,it was the year in which we were able to look back and celebrate 25 years of pioneering science since the formation of AstraZeneca in 1999.Additionally,it was the year in which we took the opportunity to look forward to 2030 and beyond as we outlined the scale of our ambition and

41、 what we aim to achieve today,tomorrow,and the day after.That ambition,set out in our Investor Day in May,is to be pioneers in science,lead in our disease areas and transform patient outcomes.By 2030,we aim to launch at least 20 new medicines and achieve$80 billion in Total Revenue,with sustained gr

42、owth thereafter.We are also pursuing ambitious science-based decarbonisation targets in support of achieving net zero by 2045.Achieving todayOutstanding science2024 was a year of scientific breakthroughs.For example,we received approvals for Voydeya(danicopan),Kavigale(sipavibart)and Datroway(datopo

43、tamab deruxtecan),taking us to a total of eight medicines A year in which we delivered medicines to millions of patients,looked back on 25 years of pioneering science and outlined the scale of our ambition for the future.Emerging Markets,achieving this milestone one year ahead of plan.This includes

44、China,where we are committed to contributing to the long-term development of the life sciences sector.We are also one of the top three pharmaceutical companies across our Europe and Canada region and are making great progress to become the number one company in Japan,where we are already number one

45、in oncology.Talented people working sustainablyOur strong progress is made possible by the commitment and efforts of our team,not least by the way they are embracing digital,data and AI to speed our progress and improve how we work.And,as we grow,we have increased our focus on learning and developme

46、nt building the skills and capabilities that will sustain our success as well as continuing to cultivate an inclusive culture that reflects our patients and communities,and supports innovation.As mentioned by Michel Demar,our Chair,in 2024 we continued to invest in collaborations and initiatives to

47、strengthen health systems.We are also investing in climate and nature action,and maintain a leading role in industry efforts to address the effects of climate change and accelerate the delivery of net-zero sustainable healthcare,while improving health outcomes and decreasing our impact on the planet

48、,reducing carbon emissions,water consumption and waste generation.Our sustained progress in reducing greenhouse gas emissions has enabled a 77.5%reduction in Scope 1 and 2 emissions from our 2015 baseline.3AstraZeneca Annual Report&Form 20-F Information 2024Corporate GovernanceAdditional Information

49、Financial StatementsStrategic ReportChief Executive Officers ReviewChief Executive Officers ReviewDelivering tomorrowIndustry-leading pipelineOur ability to deliver for patients tomorrow was underlined in 2024 by our pipeline which saw a record number of 74 regulatory events,namely submissions or ap

50、provals for our medicines in a major market,an increase of almost one third over 2023.The year also saw nine positive high-value Phase III readouts.In Oncology,Imfinzis further potential was apparent in two trials:NIAGARA demonstrated that immunotherapy could significantly extend the lives of patien

51、ts with bladder cancer while,in ADRIATIC,it was the first and only immuno-oncology to show survival benefit in limited-stage small cell lung cancer.The ECHO and AMPLIFY trials demonstrated the potential for Calquence in mantle cell lymphoma and chronic lymphocytic leukaemia.It was also great to see

52、positive results from LAURA,which cemented Tagrisso as the standard of care in unresectable EGFRm non-small cell lung cancer.DESTINY-Breast06 confirmed Enhertus potential to evolve the current HR-positive breast cancer treatment landscape.In BioPharmaceuticals,the WAYPOINT trial showed Tezspires pot

53、ential as an important new treatment option for patients with nasal polyps while,in Rare Disease,the KOMET trial results for Koselugo support its potential expanded use in adults living with NF1 PN a devastating rare genetic disease.Additionally,we had 24 pipeline progressions in 2024,being Phase II

54、 starts/progressions and Phase III investment decisions.Once again,the strength and quality of our pipeline was recognised in the granting by regulators of 28 designations across 18 projects,including Breakthrough Therapy,Priority Review or Fast Track designations.Even in such a year of success,when

55、 pushing the boundaries of science,it is normal to experience setbacks which included the termination of the vemircopan(ALXN2050)Phase II development programme for rare diseases.On such occasions,we are committed to living our Values of following the science and putting patients first,by learning fr

56、om what challenges tell us and how they can help us in realising the full potential of our medicines and benefit as many patients as possible.We also share data with the wider scientific community.Datroway exemplifies our approach.While we voluntarily withdrew applications in the US and EU for the t

57、reatment of non-squamous non-small cell lung cancer(NSCLC),it was subsequently granted Breakthrough Therapy Designation in the US for patients with previously treated advanced EGFR-mutated NSCLC.In January 2025,it was also granted Priority Review,given by the FDA to applications for medicines that,i

58、f approved,would offer significant improvements over available options.I was also delighted when,in December,our partner,Daiichi Sankyo,received the first approval for Datroway for the treatment of patients with metastatic HR-positive,HER2-negative breast cancer in Japan.This was swiftly followed in

59、 January by the approval in the US of the similar AstraZeneca-led application.Datroway offers patients an effective and better tolerated alternative to traditional chemotherapy and the approvals underscore the potential of the medicine to replace chemotherapy and deliver improved outcomes across mul

60、tiple cancer types.Health equity and climateIn Rare Disease,as part of our ambition for 2030,we are committed to reaching six times as many patients as 2022 across 100 countries with our transformative rare disease medicines.We are on track to reach this commitment in 2024,our medicines were availab

61、le in more than 70 countries.As we grow across new and existing markets,we are working with local rare disease advocates,healthcare systems and policy makers to help shape the rare disease ecosystem to shorten the diagnostic journey,improve access to treatment and ensure stakeholders understand the

62、societal value of rare disease innovation.Our efforts in Rare Disease complement those across all our therapy areas to close healthcare gaps and give people everywhere the chance to be as healthy as possible.We are doing so by embedding health equity across the whole enterprise,from science to the d

63、elivery of care.We want to better understand the factors that drive poor health outcomes among diverse populations,partnering with governments,health systems and communities to co-create solutions.The climate crisis is the largest health crisis of our time and has a significant impact on respiratory

64、 diseases which can be complex,difficult to treat,often poorly controlled and associated with a higher carbon footprint of care.We are focused on addressing this challenge by optimising care with our portfolio of respiratory medicines.At the same time,we are transitioning our inhaled medicines to a

65、next-generation propellant(NGP)with near-zero global warming potential 99.9%lower than current propellants,and were proud to make our first regulatory submission for Breztri NGP in the EU in 2024.Preparing for the day after tomorrowOur ambition for AstraZeneca extends beyond 2030 and,as shown on the

66、 next page,we are working on technologies that will,we believe,shape the future of medicine and sustain our growth.Our work is built on our internal efforts but we have also leveraged external innovation to expand and accelerate our pipeline.For example,the acquisition of Fusion brought new expertis

67、e in actinium-based radioconjugates,including one for prostate cancer,as well as state-of-the-art manufacturing capabilities,while our acquisition of Gracell in China allows us to accelerate our ambitions in cell therapy,particularly in haematology and autoimmune disease.Weight management is a parti

68、cular challenge as many affected people are living with complex,interconnected diseases.Treating each disease separately without addressing obesity as a root cause does not optimise outcomes for them or healthcare systems.Building on our existing expertise,our rapidly developing weight management po

69、rtfolio looks beyond short-term weight loss to address individual patient needs.Our aim with these therapies is to provide durable weight loss,with cardiometabolic benefit and new options for patients by targeting linked disease biology.AppreciationAstraZeneca only achieved what we did in 2024,and c

70、an only deliver our ambition for 2030 and beyond with great people in high-performing teams.On behalf of the Senior Executive Team,I would like to thank everyone in AstraZeneca for all they accomplished in 2024 and for their focus on realising our goals for people,society and the planet.Pascal Sorio

71、t Chief Executive Officer4AstraZeneca Annual Report&Form 20-F Information 2024Strategic Report For more information,see Research&Development from page 34.Investing in transformative new technologies and modalities that will shape the future of medicine and sustain AstraZenecas growth post 2030.Our i

72、nvestments in transformative R&D technologies include:Antibody drug conjugates and radioconjugates that aim to replace systemic chemotherapy and radiotherapy,see page 36.Cell therapy and T-cell engagers that are more scalable across therapy areas,see page 44.Gene therapy and gene editing that could

73、make cures possible for a range of rare diseases,see page 49.Next-generation immuno-oncology bispecifics that establish new immuno-oncology segments,see page 55.Weight management that looks beyond short-term weight loss to address individual patient needs,see page 46.What science can doMedicines for

74、 today,tomorrow and the day after.Corporate GovernanceAdditional InformationFinancial StatementsStrategic Report5AstraZeneca Annual Report&Form 20-F Information 2024What Science Can DoOur strategic priorities Our priorities reflect how we are working to deliver our Growth Through Innovation strategy

75、 and achieve our Purpose of pushing the boundaries of science to deliver lifechanging medicines.1.Science and Innovation2.Growth and Therapy Area Leadership3.People and SustainabilityScience and innovation-ledWe invest in new technologies and modalities to deliver the next wave of pipeline innovatio

76、n and lifechanging medicines.191 projects in our development pipeline119new molecular entities(NMEs)in our late-stage pipeline130NME or major life-cycle management(LCM)projects in Phase II and Phase III$13.6bninvested in our science1 Includes NME and major LCM projects up to launch in all applicable

77、 major markets.Leading in our therapy areas We focus on areas where we can transform patient outcomes through novel medicines and combinations.Total Revenue by therapy area2$22.4bn,41%Oncology$21.9bn,40%BioPharmaceuticals$8.8bn,16%Rare Disease$1.1bn,2%Other MedicinesTotal Revenue$54.1bn$54.1bn$45.8b

78、n$44.4bn2024202320222 Due to rounding,the sum of subtotals and percentages may not agree to totals.Diversified portfolio and global reach We deliver a diversified portfolio of medicines across primary care,specialty care and rare diseases through our broadbased network and increasing presence in eme

79、rging markets.Total Revenue by reporting region$23.2bn,43%$13.7bn,25%$12.2bn,23%$5.0bn,9%Total Revenue growth by reporting region322%14%27%-2%3 Actual growth percentage.Positively impacting the health of people,society and the planet BVWe operate responsibly,harnessing the power of science and innov

80、ation,and our global reach,to help build a healthier,more sustainable future.90.5m people reached by our access to healthcare programmes77.5%reduction in Scope 1 and 2 GHG emissions since 2015Rating of AA in the MSCI ESG Ratings assessment Ranked in the top five of the Access to Medicine Index 2024K

81、ey US Emerging Markets Europe Established Rest of World6AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportAstraZeneca at a GlanceWe are a global,science-led,patient-focused pharmaceutical company.We are dedicated to transforming the future of healthcare by unlocking the power of wh

82、at science can do for people,society and the planet.202420232022107100111Established RoW($bn)$111bn(+4.3%)$111bn(+4.3%)686608762US($bn)202420232022$762bn(+11.1%)$762bn(+11.1%)290269318Emerging Markets($bn)202420232022$318bn(+9.7%)$318bn(+9.7%)259240280Europe($bn)202420232022$280bn(+8.2%)$280bn(+8.2%

83、)1,3431,2191,473World($bn)202420232022The external environment presents both challenges and opportunities that require us to adapt,innovate and build trust.Global pharmaceutical salesIn 2024,Established Markets1 saw an average revenue increase of 9.7%and Emerging Markets revenue grew by 9.7%.The US,

84、China,Japan,Germany and France are the worlds top five pharmaceutical markets by 2023 sales.In 2024,the US had 51.8%(2023:51.1%;2022:49.9%)of global sales,while China had around 7%.Data based on world market sales using AstraZeneca Market definitions as set out on page 240.Changes in data subscripti

85、ons,exchange rates and subscription coverage,as well as restated IQVIA data,have led to the restatement of total market values for prior years.Source:IQVIA,IQVIA Midas Quantum Q3 2024(including US data).Reported values and growth are based on CER.Value figures are rounded to the nearest billion and

86、growth percentages are rounded to the nearest tenth.We expect both developed and developing markets,including North America,Other(Non-EU)Europe,the Indian subcontinent and Latin America to fuel pharmaceutical growth.Market growth in China is expected to remain below historical levels at a compound a

87、nnual growth rate of 2.6%(1.5%).This is due to the continued slowdown of the major hospital sector.1 Established Markets means US,Europe and Established RoW.2 North America means US.3 Non-EU countries;including the UK.4 Commonwealth of Independent States;includes Armenia,Azerbaijan,Belarus,Georgia,K

88、azakhstan,Kyrgyzstan,Moldova,Russia,Tajikistan,Turkmenistan and Uzbekistan and excludes Ukraine.$1,473bn(+9.7%)Estimated pharmaceutical sales 2028.Data is based on exmanufacturer prices at CER.Source:IQVIA.Estimated pharmaceutical market growth.Data is based on the compound annual growth rate from 2

89、023 to 2028.Source:IQVIA Market Prognosis Global 20232028.Other Europe3$71.7bn11.8%Japan$66.7bn0.9%China$159.9bn2.6%Oceania$18.1bn3.3%Southeast and East Asia$222.0bn3.6%Middle East$26.8bn7.7%Africa$22.7bn5.7%Indian subcontinent$37.8bn9.4%CIS4$28.9bn6.8%EU$290.1bn6.3%North America2$853.1bn 8.2%Latin

90、America$94.1bn14.3%Estimated pharmaceutical sales and market growth to 2028A growing pharmaceutical sector The pharmaceutical sector continues to grow against a backdrop of increasing demand for healthcare.Global pharmaceutical sales grew by 9.7%in 2024.Global healthcare spending is projected to inc

91、rease at an annual rate of 7.4%from 2023 to 2028.Healthcare in a Changing WorldCorporate GovernanceAdditional InformationFinancial StatementsStrategic Report7AstraZeneca Annual Report&Form 20-F Information 2024Healthcare in a Changing WorldThe pharmaceutical sector faces economic challenges,geopolit

92、ical uncertainty and the impacts of ageing populations and the climate crisis.Rapidly-advancing technologies offer many benefits,while demographic change is driving an increased demand for healthcare.Successful organisations are transparent,accessible,and build trust with their stakeholders.Impact o

93、f global trendsEscalating geopolitical tensions present profound challenges and opportunities for global business.Global growth remains low but stable after decline in inflation and rising protectionist policies.Accelerating pace of ageing populations in low-and middle-income countries.The world con

94、tinues to shift from a period of global cooperation to one of heightened competition and discord,producing a more volatile and confrontational geopolitical environment.This trend has acute consequences for security,trade and global collaboration.In this fragmented climate,new forms of conflict are e

95、merging.With the rise of emerging powers such as India and Brazil,sustained strategic rivalry between the US and China,as well as conflicts,such as the war in Ukraine,adversaries are beginning to wield new weapons of disinformation,cyber threats and competition space which are emerging alongside tra

96、ditional warfare.Some are choosing to exploit economic interdependence to create geopolitical dependencies,which can impact supply chains of both traditional and emerging sectors vital for the digital and green transitions.However,such trends also present opportunities as companies are encouraged to

97、 localise operations to mitigate supply chain risks.(Source:ESPAS Global Trends to 2040:Choosing Europes Future,April 2024)These growth projections remain below prepandemic averages.For advanced economies,GDP is expected to rise from 1.7%in 2023 to 1.8%in both 2024 and 2025.Growth in emerging market

98、s and developing economies is projected to slow from 4.4%in 2023 to 4.2%in both 2024 and 2025,generally as a result of increased regional conflicts and extreme weather events.Forecasts for global growth over the medium term remain at 3.1%,with low productivity growth,investment and ageing population

99、s hindering advancement.Recent election results,particularly in the US,also pose potentially significant consequences for the global economy.Prospective trade tariffs and other protectionist policies could exacerbate inflation,trade tensions and supply chain disruption across the world,and could ham

100、per mediumterm growth.Global inflation is forecast to further decline,from a peak of 9.4%in 2022 to 3.5%by the end of 2025.(Source:IMF World Economic Outlook,October 2024;Reuters,November 2024)By 2050,two thirds of the worlds ageing population is expected to live in low and middle-income countries(L

101、MICs).LMICs are disproportionately affected by noncommunicable diseases(NCDs).In total,NCDs represent 75%of nonpandemic related deaths globally.Cardiovascular diseases account for the most NCD deaths annually(19 million in 2021),followed by cancers(10 million),chronic respiratory diseases(four milli

102、on)and diabetes(two million).Nearly 75%of these global NCD deaths(32 million)occur in LMICs.This rise places increasing strain on povertyreduction initiatives and on alreadystretched healthcare systems.Increasing demand for healthcare is putting pressure on healthcare budgets which,exacerbated by th

103、e impact of the COVID-19 pandemic,is leading to downward pressure on pricing.The pandemic also saw rising concern around vaccines and the proliferation of vaccine misinformation which has potentially significant consequences for public health.(Source:WHO;The Lancet,Volume 401,Issue 10380,967-970)Two

104、 billionApproximately two billion people were eligible to vote in national elections held in over 70 countries in 2024.(Source:Statista,November 2024)3.2%Global GDP growth forecast to stabilise from 3.3%in 2023 to 3.2%in both 2024 and 2025.(Source:International Monetary Fund(IMF)World Economic Outlo

105、ok,October 2024)426 millionBetween 2020 and 2050,the number of people aged 80 years or older is expected to triple to 426 million.(Source:World Health Organization(WHO)PoliticalIncreasing geopolitical frictionEconomicActivity remains below pre-pandemic levelsSocietalGrowing population ageing and dow

106、nward pressure on pricing These risks are explored further in the Risk Overview from page 64 and Accessible and affordable healthcare from page 52.Strategic Report8AstraZeneca Annual Report&Form 20-F Information 2024Healthcare in a Changing World continuedThe significant potential of AI is already t

107、ransforming the pharmaceutical industry.The climate crisis is the greatest public health crisis of our time,increasing ill health and jeopardising access to healthcare.In research and early discovery,data and AI could accelerate the identification processes for potential new drugs and increase our u

108、nderstanding of the underlying conditions,helping new medicines to be approved and marketed for use more quickly.For medical professionals,data and AI could also boost productivity and reduce errors and costs by automating the more timeconsuming exercises of record keeping and document creation.Howe

109、ver,these new technologies have inherent risks.For example,the dangers of IP infringement and data privacy,AI hallucination and inaccuracy.Against the backdrop of the evolving uncharted regulatory landscape and high stakes associated with developing treatments for disease,these risks mean that compa

110、nies will need to put strong controls and policies in place to manage data and AI and to fully realise the benefits.(Source:McKinsey&Company,January 2024)The impacts of the climate emergency,coupled with ageing populations and a rise in chronic diseases,are worsening health inequities and adding fur

111、ther pressure to health systems.Certain populations are disproportionately impacted including women,the elderly,children,those with existing health issues and the most marginalised in society,who have often contributed least to the climate crisis,making this a health equity crisis.The immediate heal

112、th impacts of climate change could also limit the ability of primary care resources to treat longerterm,complex diseases.Furthermore,there is a growing recognition of the importance of nature and acting to protect and restore ecosystems for the health of people and the planet.(Source:The Lancet,Volu

113、me 404,Issue 10465,1847-1896)The accelerating pace of innovation offers potential for success but may exacerbate issues with trust.With the continued advancements in science and digital technologies,the rate of innovation in society is accelerating at an unprecedented pace.With the rise of AI,multio

114、mics,genebased therapies and functional genomics,the scientific industry is flourishing.Pharmaceutical companies are using these innovations to uncover novel drivers of disease and progress new drug modalities,ultimately leading to more successful outcomes for patients.While offering the potential t

115、o revolutionise the healthcare industry,this rapid rise could exacerbate alreadypresent trust issues.Concerns around the politicisation of science and the regulation of these emerging innovations remain at the heart of discussions around the acceptance of these innovations.To succeed,pharmaceutical

116、companies and the scientific industry as a whole need to more effectively communicate with the general public,engaging them in dialogue and making science more transparent and accessible.(Source:2024 Edelman Trust Barometer)$110 billionGenerative AI is estimated to produce$60 billion to$110 billion

117、in economic value annually for the pharmaceutical industry.(Source:McKinsey&Company,January 2024)167%Record-breaking increase in heat-related deaths among those over 65 years old in 2023.(Source:The Lancet,Volume 404,Issue 10465,1847-1896)73%In a 28-country survey,73%of people questioned rated the h

118、ealthcare industry trustworthy,but only 50%trusted gene-based medicine.(Source:2024 Edelman Trust Barometer)TechnologicalEmerging opportunities and risks with data and AIEnvironmentalDeep interconnection between climate and healthOutlookOpportunities and challenges for the sectorCorporate Governance

119、Additional InformationFinancial StatementsStrategic Report9AstraZeneca Annual Report&Form 20-F Information 2024Healthcare in a Changing WorldHow we deliver on our business model How we add valueImproved healthContinuous scientific innovation is vital to achieving sustainable healthcare,which creates

120、 value by:Improving health outcomes and transforming the lives of patients who use our medicines.Enabling healthcare systems to reduce costs and increase efficiency.Improving access to healthcare and healthcare infrastructure.Helping develop the communities in which we operate through local employme

121、nt and partnering.Financial valueRevenue from our Product Sales and collaboration activities generates cash flow,which helps us:Fund our investment in science and the business to drive longterm value.Follow our progressive dividend policy.Meet our debt service obligations.134m1Our main therapy area

122、medicines impact more than 134 million patient lives annually.Inspired by our Values and what science can do,we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients,society,the planet and our shareholders.Our PurposeOur ValuesOur business modelW

123、e push the boundaries of science to deliver life-changing medicines.Our Values determine how we work together and the behaviours that drive our success.They guide our decision making and define our beliefs.We follow the science We put patients first We play to win We do the right thing We are entrep

124、reneurialWe are a global pharmaceutical business with a science-led and patient-focused value proposition committed to excellence in the research,development,manufacturing and commercialisation of prescription medicines across primary care,specialty care and rare diseases.We are also committed to op

125、erating responsibly,and in an ethical and transparent way,to help build a healthier,more sustainable future.We invest resources to create financial and non-financial value that benefits patients,society,the planet and our business.Our Purpose,Values and Business Model For more information,see Busine

126、ss Review from page 32.Strategic ReportAbility to acquire,retain and develop a talented and diverse workforce.50.6%of our senior middle management roles and above are filled by womenGlobal commercial presence and skills that ensure our medicines are available to patients when needed.80 countries in

127、which we have an active presenceA leadership position in science that enables us to deliver lifechanging medicines.$13.6bn invested in our science in 2024Patent protection for our intellectual property for a reasonable period of time to prevent our new medicines being copied.90 countries where we ob

128、tained patent protectionReduction of Scope 1 and 2 GHG emissions from 2015 baseline year.77.5%Ambition Zero Carbon(Scope 1 and 2)A supply of highquality medicines,whether from our own operations or from suppliers.$26.1bn spent with suppliersEffective collaborations that supplement and strengthen our

129、 pipeline and our efforts to achieve scientific leadership.1,000 collaborations worldwideFinancial strength,including access to financing and ability to bear the financial risk of investing in the lifecycle of a medicine.$11.9bn net cash inflow from operating activities10AstraZeneca Annual Report&Fo

130、rm 20-F Information 2024Investment in discovery,development,manufacturing and commercialisation of patent-protected medicines Revenue generation Reinvestment of returnsInputs Applying our resources to address unmet medical need Outputs Improved health Returns to shareholdersOur PurposeResearch and d

131、evelopment phases 5-15 years Launch phase 5-15 yearsPost-exclusivity 20+years1 2 34 5 6 7891 The patient numbers reached for AstraZeneca medicines is an estimation of the average number of patients on therapy in a given year.For historic periods,the calculation is based upon the volume that AstraZen

132、eca manufactured globally,converted using the number of days of therapy(DoT)and the average patient compliance with their treatment.If a patient is treated by more than one AstraZeneca product they are doublecounted.This is a high-level overview of a medicines life-cycle and is illustrative only.It

133、is neither intended to,nor does it,represent the life-cycle of any particular medicine or of every medicine discovered and/or developed by AstraZeneca,or the probability of success or approval of any AstraZeneca medicine.We create financial value throughout the life-cycle of a medicineInvestment We

134、invest in the discovery,development,manufacturing and commercialisation of our pipeline of innovative prescription medicines.Revenue generation We generate revenue from Product Sales of our existing medicines and new medicine launches,as well as from our collaboration activities.Our focus is on crea

135、ting medicines that facilitate profitable future revenue generation,while bringing benefits to patients.Reinvestment We reinvest in developing the next generation of innovative medicines and in our business to provide the platform for future sources of revenue in the face of losses of key patents.We

136、 also assess opportunities to invest in valueenhancing additions to our portfolio.Launch phase duration:5-15 years 7.Launch new medicine while continuously monitoring,recording and analysing reported side effects.8.Post-launch R&D to further understand the benefit/risk profile of the medicine and li

137、fecycle management activities to understand its full potential.Post-exclusivity duration:20+years 9.Patent expiry and generic medicine entry.Research and development phases duration:5-15 years 1.Undertake scientific research to identify potential new medicines.2.Preclinical studies in the laboratory

138、 and animals to understand if the potential medicine is safe to introduce into humans.3.Phase I trials with small groups of healthy human volunteers(small molecules)or patients(biologics)to understand how the potential medicine is absorbed into the body,distributed and excreted.4.Phase II trials on

139、small to mediumsized groups of patients to test effectiveness,safety and tolerability of the medicine and determine optimal dose.5.Phase III trials in a larger group of patients to gather information about effectiveness and safety of the medicine and evaluate the overall benefit/risk profile.6.Seek

140、regulatory approvals for manufacturing,marketing and selling the medicine.Life-cycle of a medicine For more information on our pipeline progression,see our Development Pipeline Supplement on our website, Annual Report&Form 20-F Information 2024Corporate GovernanceAdditional InformationFinancial Stat

141、ementsStrategic ReportOur Purpose,Values and Business Model202420232022$11,861m$10,345m$9,808m$11,861m$11,861mNet cash inflow from operating activities$8.21$7.26$6.66Core EPS202420232022$8.21$8.21202420232022$4.54$3.84$2.12$4.54$4.54Reported EPSKey Performance IndicatorsCash generation is a key driv

142、er of longterm shareholder returns and facilitates reinvestment in our pipeline,which is critical for delivering new medicines and future value.Earnings per share(EPS)is an important profitability metric and a key driver of shareholder value.Actual growth 2024+15%2023+5%2022+64%Actual growth 2024+13

143、%2023+9%2022+26%CER growth2024+19%2023+15%2022+33%Actual growth 2024+18%2023+81%2022 n/mCER growth2024+29%2023+96%2022 n/mKey Used for remuneration of Executive Directors Material sustainability metric,is independently assured by Bureau Veritas,see definitions from page 234.For more information on:O

144、ur Core measures see the Financial Review from page 67.How Group financial targets are considered when calculating the annual bonus,see page 121.Ambition 2030 Our ambition is to be pioneers in science,lead in our disease areas and transform patient outcomes.As announced at our Investor Day in May 20

145、24,by 2030,we aim to launch at least 20 new medicines and achieve$80 billion in Total Revenue with sustained growth thereafter.Our Key Performance Indicators and remuneration We measure our productivity and success against our Key Performance Indicators(KPIs),which are aligned to our strategic prior

146、ities.Several KPIs in this section are used to measure the remuneration of Executive Directors,allowing us to disclose aggregated targets without disclosing sensitive commercial information at the individual KPI level.Any variances between the KPI and values used in determining remuneration are expl

147、ained in the Directors Remuneration Report from page 112.Since 2021,we have included the delivery of our Ambition Zero Carbon commitments in our executive incentive arrangements.Achieve Group Financial TargetsOur ambition is to launch at least 20 new medicines by 2030.AstraZeneca:is science and inno

148、vation led is focused on our chosen therapy areas:Oncology;BioPharmaceuticals(comprising Cardiovascular,Renal&Metabolism(CVRM),Respiratory&Immunology(R&I)and Vaccines&Immune Therapies(V&I);and Rare Disease is focused on patients and a diversified portfolio that spans across primary care,specialty ca

149、re and rare disease has global strength with a balanced presence across regions has a commitment to people,society and the planet.Our Growth Through Innovation strategy has three priorities,whose effective delivery will help us achieve our financial targets.Our capital allocation priorities include:

150、investing in the business and pipeline;maintaining a strong,investment-grade credit rating;potential value-enhancing business development opportunities;and supporting the progressive dividend policy.1.Science and Innovation3.People and Sustainability2.Growth and Therapy Area LeadershipAchieve Group

151、Financial Targets12AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportStrategic ReportOur Strategy and Key Performance Indicators241302293241241Pipeline progression events 202420232022202420232022741562723741 741 Regulatory events1 The target of 20 reflects medicines approved since

152、October 2022 and replaces the goal of delivering 15 new medicines between 2023 and 2030 referred to in our 2023 annual report.ThreeNME approvals74regulatory events24pipeline progression events191projects included in our pipeline,of which 169 are in the clinical phase of development19NME projects in

153、pivotal trials or under regulatory review covering 29 indications17projects were discontinued2024 developments For more information,see:Research&Development from page 34 of the Business Review.AI from page 44 of the Business Review.2024 Group scorecard assessment on page 121 for performance against

154、the Group scorecard.Key Performance Indicators BVOur science measures incentivise the development of NMEs and the maximisation of the potential of existing medicines.Pipeline progression events(Phase II NME starts/progressions and Phase III investment decisions)measure innovation and sustainability.

155、Regulatory events(regulatory submissions and approvals)demonstrate the advancement of this innovation to patients and the value to the Group.1 24 against our Group scorecard for determining annual bonus.2 30 against our Group scorecard for determining annual bonus.3 25 against our Group scorecard fo

156、r determining annual bonus.1 52 against our Group scorecard for determining annual bonus.2 46 against our Group scorecard for determining annual bonus.3 50 against our Group scorecard for determining annual bonus.Accelerate platform of therapeutic modalities By harnessing innovation from around the

157、world,we are pioneering new ways of targeting the drivers of disease and accelerating promising therapeutic modalities,including novel radioconjugates,cell therapy and genomic medicines.This breadth of research and clinical development exemplifies the diversity of approaches and technologies we are

158、applying across our growing pipeline,alongside pipeline combinations that strengthen our therapy area leadership.Transform R&D ways of workingWe are transforming processes,data and how we work across R&D and reimagining patient recruitment and retention to help meet our portfolio ambition and delive

159、r medicines to patients faster.We continue to expand our capabilities by making our ways of working smarter,and by introducing new digital tools,connected data and simpler processes.Advances in science and technology are revolutionising the way we work,enabling us to push the boundaries to deliver n

160、ew and better medicines and treatments more quickly to more patients.Our strategic focus areasDeliver the next wave of pipeline innovationWe are rapidly advancing an industry-leading pipeline and investing in new technologies and modalities to deliver the next wave of medicines across therapy areas.

161、Our diverse pipeline comprises around 200 projects spanning multiple mechanisms and modalities,designed to improve outcomes,drive clinical remission and provide cures for patients around the world.Science and Innovation Eight new molecular entities delivered against our Ambition 2030 of launching at

162、 least 20 new medicines.113AstraZeneca Annual Report&Form 20-F Information 2024Corporate GovernanceAdditional InformationFinancial StatementsStrategic ReportOur Strategy and Key Performance Indicators$54,073m$45,811m$44,351m$54,073m$54,073mTotal Revenue202420232022Realise world-class supply chains W

163、ith nextgeneration technologies and modalities,we aim to launch 20 new medicines and achieve industryleading growth through sustainable worldclass supply chains.We will harness AIpowered drug development,continuous,autonomous manufacturing techniques and realtime product release,taking us from smart

164、 to intelligent supply.We strive to leverage green technologies to drive lowcarbon products and sites by design,increase circularity by reducing waste across our manufacturing sites and accelerate our supply chain and supplier decarbonisation.2024 developmentsTotal Revenue,comprising Product Sales,A

165、lliance Revenue and Collaboration Revenue,increased by 18%(21%at CER)to$54,073 million.Alliance Revenue increased by 55%(55%at CER)to$2,212 million.Collaboration Revenue increased by 56%(54%at CER)to$923 million.Grew Total Revenue across our Therapy Areas:Oncology 21%(24%at CER)to$22,353 million;CVR

166、M 18%(20%at CER)to$12,517 million;R&I 23%(25%at CER)to$7,876 million;V&I 8%(8%at CER)to$1,462 million;and Rare Disease 13%(16%at CER)to$8,768 million.Total Revenue in the US grew by 22%to$23,235 million.In Emerging Markets it grew by 14%(22%at CER)to$13,675 million and in Europe it grew by 27%(26%at

167、 CER)to$12,188 million.Key Performance IndicatorsOur Total Revenue measure reflects the importance of incentivising sustainable growth in both the short and long term.We are working across our therapy areastotransform care and meet the increasing demand for healthcare by improving access to our medi

168、cines,expanding treatment options and enabling patients to take control oftheirown health.Our strategic focus areasAchieve industry-leading growth in our therapy areasOur diversified portfolio across therapy areas with broad geographic presence,will help us achieve industryleading growth.Transform c

169、are AstraZeneca is collaborating with governments,healthcare systems and providers to make a positive impact on the global burden of disease and support healthcare systems to become more resilient for future generations,helping deliver better outcomes for all.In partnership with healthcare systems a

170、round the world,we aim to reduce disease progression,hospital admissions and premature deaths by half enhancing the lives of millions of people.We envision a health system that is proactive and integrated with patientcentred care models.Our focus is on four key areas of healthcare delivery:proactive

171、 screening and early diagnosis guideline adoption at the practice level specialist pathways and personalised care building resilient health systems.Growth and Therapy Area LeadershipActual growth 2024+18%2023+3%2022+19%CER growth2024+21%2023+6%2022+25%Through partnering with healthcare systems from

172、more than 40 countries,our practice-changing initiatives have already enabled millions more people to gain access to guideline-directed care.For details of how Total Revenue is considered when calculating the annual bonus,see from page 121.For more information,see:Therapy Area Review from page 16.Af

173、fordability and pricing on page 52 and Operations from page 41 of the Business Review.Our Strategy and Key Performance Indicators continued14AstraZeneca Annual Report&Form 20-F Information 2024Strategic Report86%84%86%84%84%Employee belief that AstraZeneca is a great place to work12024202320222024 2

174、5/272023 25/272022 7/9Green AmberRed25/2725/27Sustainability KPIs performance22024 developments BV We continued to invest in our people to ensure we recruit,retain and develop a talented workforce.We continued to score highly in our Pulse survey for questions relating to our Purpose,direction,patien

175、t centricity and employee commitment.We continued to invest in global collaborations,Group initiatives and local partnerships to strengthen health systems.We maintained a leading role in industry efforts to address the impact of climate change and accelerate the delivery of netzero healthcare,while

176、improving health outcomes and minimising our environmental impact.Our Ambition Zero Carbon strategy delivered further reductions in our GHG emissions across our operations Scopes 1 and 2 and we made progress on initiatives,including through supply chain decarbonisation,as we work towards achieving a

177、 50%target reduction in Scope 3 emissions by 2030.We announced the completion of the clinical programme for submissions in Europe,UK and China to support the transition of the first inhaled medicine delivered by pressurised metereddose inhaler(Breztri/Trixeo)to a nextgeneration propellant(NGP)with n

178、earzero Global Warming Potential.Key Performance Indicators BVOur People KPI is based on our Pulse survey measure of those employees who believe that AstraZeneca is a great place to work.Our Sustainability KPIs,including climaterelated targets,reflect our success in achieving our sustainability goal

179、s.They are based on nine focus areas that have guided our sustainability strategy since 2021.Recognising the interconnection betweenbusiness growth,the needs ofsociety and our dependency on nature,wepromote health equity and resilient healthcare,and play an active role inaddressing the climate crisi

180、s.Wecultivate an inclusive and diverse work environment where employees can thrive and are empowered to make an impact for people,society and the planet.Our strategic focus areasDeliver a great employee experience We are dedicated to being a great place to work by maintaining employee engagement,del

181、ivering our inclusion and diversity strategy,and offering learning and development programmes.Lead on climate,equity and resilience We are harnessing the power of science and innovation in ways that positively impact more patients and healthcare systems while reducing our impact on the environment.W

182、e are working towards absolute reductions in all our direct and indirect GHG emissions sources across the value chain Scope 1,2 and 3 and decoupling carbon emissions from revenue growth.We are advancing our sustainability priorities across the interconnected dimensions of climate and nature,focusing

183、 on mitigating the impacts of climate change,restoring and protecting nature,building resilient health systems and improving health equity.Enable an agile organisationWe are harnessing the potential of technology,simplifying how we work and scaling our business for the future.For more information,se

184、e:People and Sustainability from page 47 of the Business Review.For more information on our Sustainability KPIs,including definitions,methodology and restatements,see our Sustainability Data Annex at and Sustainability Through science,we can drive positive change and help build a healthier future fo

185、r people,society and theplanet.1 Source:November Pulse survey for each year.2 In 2024,we assessed our performance against 27 publicly available targets.At least 90%of targets need to be on plan or target met to achieve a rating of green;at least 70%for amber;and red signifies any percentage below th

186、is.15AstraZeneca Annual Report&Form 20-F Information 2024Corporate GovernanceAdditional InformationFinancial StatementsStrategic ReportOur Strategy and Key Performance Indicators Redefine cancer care OncologySource:IQVIA.AstraZeneca focuses on specific segments within this overall therapy area marke

187、t.Oncology Therapy Area submarket totals($217.1bn)do not sum up exactly to the therapy area total($218.8bn)due to rounding.2024 overview Commercial delivery and sales performance driven by five multiblockbuster medicines:Tagrisso,Lynparza,Calquence,Imfinzi and Enhertu.Broad penetration of our Oncolo

188、gy medicines with 22 major market approvals across 15 indications.First approval for our latest new medicine Datroway(Dato-DXd)in the US and Japan.10 positive Phase III readouts across multiple tumour types including lung,breast,bladder,prostate and blood cancers,including two from China-led trials.

189、Total Revenue$22,353mup 21%(24%at CER)2023:$18,447m2022:$15,539m$65.0bn Small molecule targeted agents$52.6bn Immune checkpoint inhibitors$47.8bn Monoclonal antibodies(mAbs)$25.5bn Chemotherapy$21.0bn Hormonal therapies$4.0bn PARP inhibitors$1.2bn Other oncology therapies$218.8bnAnnual worldwide mar

190、ket valueTherapy area world market(MAT Q3-24)Therapy Area ReviewUnmet medical need and world market2ndCancer is the second leading cause of death worldwide.16.3mBy 2040,cancer is expected to account for 16.3 million deaths annually across the globe.Over 30mThe global burden of cancer is expected to

191、grow,with over 30 million newly diagnosed patients estimated by 2040.Two thirds of those patients are expected to be in low-to-middle income countries.We are leading a revolution to transform cancer care.16AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportOur strategy in OncologyOu

192、r ambition is to eliminate cancer as a cause of death.We seek to transform outcomes for people living with cancer through innovative medicines,powerful combinations and a world-class,purpose-driven team.Our commercial strategy to transform patient outcomes centres on three key areas:Medicines that m

193、atter:building transformative brands that raise the standard of care for patients.Leveraging scale:strengthening leadership and expertise in key tumour types(lung,haematology,genitourinary/gynaecological,breast and gastrointestinal).Transforming patient care:closing the care gaps to deliver optimal

194、care for every patient,improving access and building more resilient healthcare systems through partnerships.Our R&D strategy focuses on these key pillars:1.Innovative science across seven scientific platforms that attack cancer from multiple angles:a.Tumour drivers and resistance targeting genetic m

195、utations and resistance mechanisms that can disrupt the ability of cancer cells to survive and proliferate.b.DNA damage response targeting the DNA repair process to block cancer cells from reproducing.c.Antibody drug conjugates(ADCs)and radioconjugates highly potent cancer-killing agents delivered d

196、irectly to cancer cells via a linker attached to a targeting molecule such as an antibody,peptide or small molecule.d.Epigenetics targeting changes to genome expression caused by cancer.e.Immuno-oncology activating the bodys own immune system to help fight cancer.f.Cell therapies harnessing living c

197、ells to target cancer.g.Immune engagers redirecting the immune systems T-cells to the tumour and amplifying that patients own anti-cancer immune response.2.Treating cancer earlier and smarter with early detection and personalised treatments.3.Pioneering new technologies to help us advance science an

198、d achieve the next wave of breakthroughs.Full details are given in the Development Pipeline and Patent Expiries of Key Marketed Products Supplements on our website, marketed products Product DiseaseTotal RevenueCommentaryTagrisso(osimertinib)Lung cancer$6,580m,up 13%(16%at CER)Approved in 112 countr

199、ies for adjuvant early-stage EGFRm NSCLC and in 113 countries for 1st-and 2nd-line treatment of advanced EGFRm NSCLC.Approved in combination with chemotherapy in 1st-line advanced EGFRm NSCLC in 27 countries and in several countries as a maintenance treatment after definitive chemoradiation in unres

200、ectable Stage III EGFRm NSCLC.Imfinzi(durvalumab)Lung cancerBiliary tract cancer(BTC)Liver cancerEndometrial cancer$4,717m,up 17%(21%at CER)Approved in 97 countries in the curative-intent setting of unresectable,Stage III NSCLC and in 63 countries for metastatic NSCLC.Approved in nine countries for

201、resectable NSCLC.Approved in 97 countries for extensive-stage SCLC and in three countries including the US for limited-stage SCLC.Approved in 89 countries for locally advanced or metastatic BTC.Approved in 71 countries in combination with Imjudo for uHCC and 33 countries as monotherapy.Approved in 3

202、6 countries for advanced or recurrent endometrial cancer.Calquence(acalabrutinib)CLLMCLSLL$3,129m,up 24%(25%at CER)Approved in 92 countries for the treatment of chronic lymphocytic leukaemia(CLL)and in 47 countries for the treatment of adult patients with relapsed or refractory mantle cell lymphoma(

203、MCL)who have received at least one prior therapy;approved in the US for previously untreated MCL patients.Approved in the US,Japan and China for small lymphocytic lymphoma(SLL).Lynparza(olaparib)Ovarian cancerBreast cancerPancreatic cancerProstate cancerEndometrial cancer$3,672m,up 20%(22%at CER)App

204、roved in 101 countries as maintenance therapy for platinum-sensitive relapsed ovarian cancer,101 countries for 1st-line BRCAm ovarian cancer,and in 100 countries with bevacizumab for HRD-positive advanced ovarian cancer.Approved in 101 countries for gBRCAm,HER2-negative early breast cancer and in th

205、e metastatic setting in 86 countries.Approved in 99 countries for gBRCAm metastatic pancreatic cancer.Approved in 101 countries for HRR gene-mutated mCRPC(BRCAm only in certain countries)and in 90 countries in combination with abiraterone for the 1st-line treatment of adult patients with mCRPC.Appro

206、ved in 31 countries as maintenance therapy in advanced or recurrent endometrial cancer that is pMMR.Enhertu(trastuzumab deruxtecan)Breast cancerLung cancerGastric cancerTumour agnostic$1,982m,up 54%(58%at CER)Approved in more than 75 countries for HER2-positive metastatic breast cancer following one

207、 or more prior anti-HER2-based regimens.Approved in more than 70 countries for HER2-low metastatic breast cancer following chemotherapy.Approved in more than 50 countries for previously treated HER2-mutant metastatic NSCLC and in 60 countries for previously treated HER2-positive advanced gastric or

208、gastroesophageal junction adenocarcinoma.Approved in the US and several countries for previously treated metastatic HER2-positive(IHC 3+)solid tumours.Also approved in the US for HR-positive,HER2-low or HER2-ultralow metastatic breast cancer following one or more endocrine therapies.Zoladex(gosereli

209、n acetate implant)Prostate cancerBreast cancer$1,097m,up 11%(17%at CER)Approved in 122 countries for the treatment of prostate cancer and in 64 countries for the treatment of breast cancer in premenopausal women.Imjudo(tremelimumab)Liver cancerLung cancer$281m,up 29%(31%at CER)Approved in 71 countri

210、es in combination with Imfinzi for unresectable HCC and in 63 countries in combination with Imfinzi and chemotherapy for metastatic NSCLC.Truqap(capivasertib)Breast cancer$430m,up$424mApproved in more than 45 countries in combination with Faslodex for HR-or ER-positive,HER2-negative locally advanced

211、 or metastatic breast cancer with one or more biomarker alterations(PIK3CA,AKT1 or PTEN)following recurrence or progression.Approved in Australia for HR-positive,HER2-negative locally advanced or metastatic breast cancer following recurrence or progression.Orpathys(savolitinib)Lung cancer$46m,stable

212、 (up 2%at CER)Approved in China and Macau for treatment of locally advanced or metastatic NSCLC with MET gene alterations.Datroway(datopotamab deruxtecan)Breast cancern/aApproved in the US and Japan for patients with previously treated metastatic HR-positive,HER2-negative breast cancer.17AstraZeneca

213、 Annual Report&Form 20-F Information 2024Corporate GovernanceAdditional InformationFinancial StatementsStrategic ReportTherapy Area Review|Oncology2024 review strategy in actionLung cancerScientific advances in early detection and precision medicine are strengthening the potential to offer meaningfu

214、l patient outcomes and long-term survival in lung cancer.We have a comprehensive portfolio,along with a promising pipeline of potential new medicines and combinations across diverse mechanisms of action.By 2030,we aim to have an AstraZeneca medicine for more than half of all patients treated for lun

215、g cancer.Tagrisso is the world-leading third-generation TKI and backbone therapy for EGFRm NSCLC across multiple stages.Across markets we see continued demand growth for Tagrisso in both the adjuvant and metastatic settings.Tagrisso with the addition of chemotherapy was approved in more than 45 coun

216、tries,including the US,EU,China and Japan,for the 1st-line treatment of adult patients with locally advanced or metastatic EGFRm NSCLC.Approvals were based on positive results from the FLAURA2 Phase III trial,which showed Tagrisso in combination with chemotherapy demonstrated a statistically signifi

217、cant and clinically meaningful improvement in PFS.Positive results from the LAURA Phase III trial showed Tagrisso demonstrated a statistically significant and highly clinically meaningful improvement in PFS in patients with unresectable,Stage III EGFRm NSCLC.Tagrisso is now approved for these patien

218、ts in the US,Switzerland,the EU and China.Since its first approval,more than 374,000 patients have been treated with Imfinzi and its the only approved immunotherapy in limited-stage SCLC and the global SoC in the curative-intent setting of unresectable,Stage III NSCLC in patients whose disease has n

219、ot progressed after CRT.Imfinzi was approved in the US and several other countries for the perioperative treatment of resectable,early-stage(IIa-IIIb)NSCLC with no known EGFRm or ALK rearrangements,based on the AEGEAN Phase III trial.Imfinzi was approved in the US and Switzerland and recommended for

220、 approval in the EU for patients with limited-stage SCLC whose disease had not progressed following platinum-based concurrent CRT based on the positive ADRIATIC Phase III trial results.Results from the ADJUVANT BR.31 Phase III trial showed Imfinzi did not achieve statistical significance for disease

221、-free survival in early-stage(Ib-IIIa)NSCLC after complete tumour resection in patients whose tumours express PD-L1 on 25%or more tumour cells.Final OS results were announced from the TROPION-Lung01 Phase III trial which showed a favourable trend in OS with Datroway in patients with previously treat

222、ed advanced or metastatic non-squamous NSCLC.Data from TROPION-Lung01 using a predictive computational pathology biomarker was also presented at the World Conference on Lung Cancer.Ongoing Phase III trials in 1st-line NSCLC have the potential to validate the use of this patient selection biomarker.D

223、atroway is jointly developed and commercialised with Daiichi Sankyo.Datroway was granted Priority Review in the US for the treatment of patients with locally advanced or metastatic EGFRm NSCLC who have received prior systemic therapies,including an EGFR-directed therapy,based on results from the TRO

224、PION-Lung05 Phase II trial and supported by data from the TROPION-Lung01 Phase III trial.The companies voluntarily withdrew an application in the US,as well as the marketing authorisation application in the EU,for Datroway for patients with advanced or metastatic non-squamous NSCLC.Enhertu is the fi

225、rst HER2-directed therapy approved for patients with HER2-mutant metastatic NSCLC.In 2024,it received conditional approval in China in this setting based on the DESTINY-Lung02 and DESTINY-Lung05 Phase II trials.Enhertu is jointly developed and commercialised with Daiichi Sankyo.Breast cancerWe are a

226、iming to redefine clinical practice and transform outcomes across all subtypes and stages of breast cancer.Our portfolio of approved medicines and promising medicines in development leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment.Enhertu i

227、s the established SoC in HER2-positive(DESTINY-Breast03)and HER2-low(DESTINY-Breast04)metastatic breast cancer.Positive results from the DESTINY-Breast06 Phase III trial showed that Enhertu provided a statistically significant and clinically meaningful improvement in PFS for patients with HER2-low o

228、r HER2-ultralow metastatic breast cancer who had received at least one line of endocrine therapy.Enhertu is now approved in the US in this setting based on these results.Continued strong demand growth with strong uptake for Truqap worldwide in a biomarker-altered subgroup of HR-positive,HER2-negativ

229、e metastatic breast cancer.Truqap was approved in the EU and Japan in combination with Faslodex as the first AKT-inhibitor for patients with HR-positive,HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations(PIK3CA,AKT1 or PTEN)following disease progression

230、 or recurrence,based on the CAPItello-291 Phase III trial.Truqap in combination with paclitaxel did not meet a primary endpoint of OS in the CAPItello-290 Phase III trial in patients with locally advanced or metastatic triple-negative breast cancer.The TROPION-Breast01 Phase III trial of Datroway ve

231、rsus chemotherapy,which previously met the dual primary endpoint of PFS,did not meet its OS endpoint in patients with previously treated metastatic HR-positive,HER2-low or HER2-negative breast cancer.Datroway is approved in the US and Japan and recommended for approval in the EU in this setting.Lynp

232、arza remains the first-in-class PARP inhibitor across four tumour types as measured by total prescription volume,achieving 10%growth in 2024 versus 2023,and is the only PARP inhibitor to improve survival in early breast cancer.Updated results from the OlympiA Phase III trial showed Lynparza demonstr

233、ated sustained,clinically meaningful improvements in OS,invasive disease-free survival and distant disease-free survival at six years for patients with germline BRCA-mutated(gBRCAm)HER2-negative high-risk early breast cancer.Lynparza was recently approved in China for these patients.Genitourinary/gy

234、naecological cancersIn genitourinary cancers,we aim to transform treatment paradigms with our portfolio of approved medicines and a diverse pipeline of innovative treatments to help more patients.This includes solidifying Lynparza plus abiraterone and prednisone as a SoC in 1st-line metastatic castr

235、ation-resistant prostate cancer(mCRPC)and aiming to bring Imfinzi as a new treatment option for muscle-invasive bladder cancer(MIBC).In gynaecological cancers,we will continue to redefine survival expectations,maximising Lynparzas position as a SoC in advanced ovarian cancer,and in combination with

236、Imfinzi in endometrial cancer.Imfinzi and Lynparza were approved in several countries for the treatment of patients with advanced or recurrent endometrial cancer based on the DUO-E Phase III results:In the US,Imfinzi with platinum-based chemotherapy was approved as 1st-line treatment followed by Imf

237、inzi monotherapy for patients with dMMR disease.18AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportTherapy Area Review|Oncology continued In the EU,Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been approved for patients with pMMR disease.Imf

238、inzi plus chemotherapy followed by Imfinzi alone has also been approved for patients with dMMR disease.In Japan,Imfinzi with platinum-based chemotherapy was approved as 1st-line treatment followed by Imfinzi monotherapy for patients regardless of mismatch repair status.Imfinzi plus chemotherapy as 1

239、st-line treatment followed by Lynparza and Imfinzi has also been approved for patients with pMMR disease.Results from the NIAGARA Phase III trial showed Imfinzi in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in event-free survival and

240、OS for patients with MIBC.It is now under Priority Review in the US in this setting.Positive results from the CAPItello-281 trial showed Truqap in combination with abiraterone and androgen deprivation therapy demonstrated a statistically significant and clinically meaningful improvement in radiograp

241、hic PFS in PTEN-deficient metastatic hormone-sensitive prostate cancer(mHSPC).Gastrointestinal cancersWe have a broad and robust portfolio and development programme for the treatment of gastrointestinal(GI)cancers in many stages and disease types across multiple approved and potential new medicines.

242、Imfinzi in GI cancers was a major growth driver in 2024,based on market approvals in BTC(TOPAZ-1)and HCC(HIMALAYA)worldwide.Enhertu received conditional approval in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer based on the DESTINY-Gastric06 and DESTI

243、NY-Gastric01 trials.Data from a Phase I trial of C-CAR31,a novel autologous armoured Glypican 3(GPC3)targeting chimeric antigen receptor T-cell(CAR-T)therapy,showed encouraging safety and preliminary efficacy results in patients with HCC.Blood cancersIn haematology,we are unleashing the potential of

244、 Calquence,the current SoC in multiple forms of blood cancer,while pushing the boundaries of science to redefine care through ambitious clinical development,deep clinical insights and a focus on improving the patient experience.Positive results from the AMPLIFY Phase III trial showed a fixed-duratio

245、n of Calquence in combination with venetoclax,with or without obinutuzumab,demonstrated a statistically significant and clinically meaningful improvement in PFS in previously untreated CLL.Results from the ECHO Phase III trial showed that Calquence plus chemoimmunotherapy significantly improved PFS

246、as a 1st-line treatment of patients with MCL.Calquence is now approved in the US in this setting.Early data from our novel CD19xCD3 bispecific T-cell engager,surovatamig,(AZD0486)in follicular lymphoma and diffuse large B-cell lymphoma showed promising clinical efficacy and safety profile.Pan-tumour

247、Together with Daiichi Sankyo,we are exploring the role of HER2-directed therapies in treating multiple solid tumour types.We see encouraging early uptake for Enhertu following tumour-agnostic approvals worldwide.Enhertu was approved in the US for previously treated patients with metastatic HER2-posi

248、tive solid tumours based on three Phase II trials(DESTINY-PanTumor02,DESTINY-Lung01 and DESTINY-CRC02)which showed clinically meaningful responses across a broad range of tumours.The approval marked the first tumour-agnostic approval of a HER2-directed therapy and an ADC.The transformative potential

249、 of cell therapiesCell therapies are one of the transformative technologies in which we are investing to bring their curative potential to patients.We accelerated their delivery with the acquisition of Gracell,whose FasTCAR platform significantly shortens manufacturing time and aims to improve the a

250、ctivity of therapeutic CAR-Ts,as well as reduce treatment waiting times.A collaboration with the Moffitt Cancer Center is designed to accelerate our cell therapy pipeline and we are also progressing our T-cell receptor therapies from our Neogene acquisition.We have announced a new manufacturing faci

251、lity in Maryland,US,to expand capacity.19AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportAdditional InformationFinancial StatementsCorporate GovernanceTherapy Area Review|OncologyOur ambition is to transform care for billions of people living with chronic diseases and deliver lon

252、g-lasting immunity.We are working to intervene earlier to protect vital organs,slow or reverse disease progression,and achieve remission for often degenerative,debilitating and life-threatening conditions,so many more people can live better,healthier lives.Transform care for billionsBioPharmaceutica

253、lsTherapy Area Review20AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportTotal Revenue$12,517mup 18%(20%at CER)2023:$10,628m2022:$9,211mTotal Revenue$7,876mup 23%(25%at CER)2023:$6,404m2022:$5,963mTotal Revenue$1,462mup 8%(8%at CER)2023:$1,357m2022:$4,836mOur ambition is to improve

254、 care to save lives for the millions living with cardiovascular,renal and metabolic diseases,stop disease progression and,ultimately,pave the way to a cure.Our ambition is to transform respiratory and immunology care for millions of patients worldwide,moving beyond symptom control to disease modific

255、ation,remission and,one day,cure.Our ambition is to develop and deliver innovative vaccines and antibodies to protect patients from serious viral and bacterial infections,providing long-lasting immunity to millions.Unmet medical need and world market1.4 billion people across the globe are affected b

256、y CVRM diseases.4 of the top 7causes of death worldwide are predicted to be CVRM diseases by 2040.Unmet medical need and world market500 millionpeople worldwide have chronic respiratory diseases,which carry a high disease burden.40 millionpeople worldwide have the immune-mediated diseases we are tar

257、geting,with few achieving remission.$4.8 trillionthe estimated global burden of chronic obstructive pulmonary disease(COPD)by 2050,a leading cause of hospital admissions and the worlds third leading cause of death.Excluding COVID-19.Unmet medical need and world market300,000 hMPV and RSV-related hos

258、pitalisations combined among older adults in the US each year.One billion cases of seasonal influenza annually.Up to 4%of the population is immunocompromised and is at a higher risk of hospitalisation from COVID-19 than the general population.2024 overview Farxiga retained its position as the number

259、 one SGLT2 inhibitor worldwide by volume,growing faster than the overall SGLT2 market in all major regions,driven by continued demand in heart failure(HF)and chronic kidney disease(CKD).Wainzua recommended for approval in the EU for the treatment of adult patients with polyneuropathy of hereditary t

260、ransthyretin-mediated amyloidosis.The CVRM pipeline was bolstered by an exclusive licence agreement with CSPC Pharmaceutical Group Ltd.to develop an early stage,novel small molecule Lipoprotein(a)(Lp(a)disruptor.2024 overview Achieved double-digit growth driven by key launch brands(Breztri,Fasenra,T

261、ezspire,Saphnelo,Airsupra).Tezspire secured blockbuster status with combined sales recorded by Amgen and AstraZeneca of$1.2 billion,of which AstraZeneca recorded Total Revenue of$684 million.Progressed the late-stage portfolio including four major market approvals and four Phase II and Phase III dat

262、a readouts.Submitted the first regulatory filings to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential(GWP).2024 overview Completed the acquisition of Icosavax enhancing late-stage pipeline with potential first-in-class RSV/human metapneumovirus(

263、hMPV)combination vaccine.Beyfortus demonstrated a 90%reduction in RSV-related hospitalisations in its first season.Following 2023 and 2024 approvals in the US and China,Beyfortus is now approved in 50 countries as the first and only RSV lower respiratory tract disease(LRTD)preventative option for a

264、broad infant population.FluMist was approved in the US as the only influenza vaccine for self-or caregiver-administration at home,recognised in TIME Magazine 2024 Innovations of the Year.Cardiovascular,Renal&Metabolism Respiratory&ImmunologyVaccines&Immune TherapiesCorporate GovernanceAdditional Inf

265、ormationFinancial StatementsStrategic Report21AstraZeneca Annual Report&Form 20-F Information 2024Therapy Area Review|BioPharmaceuticals$194.1bn Diabetes$39.5bn High blood pressure$21.8bn Abnormal levels of blood cholesterol$9.6bn CKD$7.2bn Thrombosis$5.0bn CKD-associated anaemia$1.0bn Hyperkalaemia

266、$72.6bn Other CV$323.0bn$323.0bnAnnual worldwide market valueTherapy area world market(MAT Q3-24)Our strategy in CVRMOur ambition is to improve and save lives for the millions of people who are living with the complexities of CVRM diseases.The impact of CVRM diseases on people,society and our planet

267、 is immense and growing,yet these diseases remain underdiagnosed,undertreated,and their interconnections under-recognised.By 2040,it is expected that CVRM diseases and comorbidities will account for four of the top seven causes of death globally(heart disease,diabetes,kidney disease and stroke),and

268、five of the top eight leading risk factors of premature death(high blood pressure,BMI,glucose,cholesterol and impaired kidney function).These are complex and interconnected conditions,with the majority of patients living with two or more of them.We are building the broadest and deepest pipelines thr

269、ough novel mechanisms and combinations to:Slow and stop cardiorenal disease and protect vital organs.Address major risk factors of hypertension,dyslipidaemia and obesity to help prevent them.By understanding their interconnections and targeting the mechanisms that drive CVRM diseases,we will be able

270、 to detect,diagnose and treat people earlier and more effectively,stop disease progression and,ultimately,pave the way to a cure.2024 review strategy in actionOur strategy focuses on three areas:cardiovascular,renal,and metabolic diseases.Cardiovascular(CV)CV disease is the leading cause of death wo

271、rldwide.Our ambition is to reduce CV disease by addressing risk factors such as hypertension control and dyslipidaemia,as well as treating CVRM comorbidities.In February 2024,together with Ionis,we received Fast Track designation in the US for Wainua in the treatment of transthyretin-mediated amyloi

272、d cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis(ATTRv)in adults.Wainzua(Wainua in the US)was recommended for approval in the EU for the treatment of ATTRv in adult patients with Stage 1 or Stage 2 polyneuropathy.This follows the US FDA approval in 2023.New real-world e

273、vidence demonstrated the need for earlier diagnosis and rapid initiation of guideline-directed medical therapy in HF patients.REVOLUTION HF showed that delayed diagnosis led to increased hospitalisations,mortality rates,and four-times higher healthcare costs.Baxdrostat,an aldosterone synthase inhibi

274、tor,has progressed into Phase III trials for treatment-resistant and uncontrolled hypertension.Targeting aldosterone aims to reduce the risk of Key marketed products ProductDiseaseTotal Revenue CommentaryFarxiga/Forxiga(dapagliflozin)Type 2 diabetes(T2D)Heart failure(HF)Chronic kidney disease(CKD)$7

275、,717m,up 29%(31%at CER)Farxiga continues to be the number one SGLT2 inhibitor worldwide by volume,growing faster than the overall SGLT2 market in all major regions,driven by continued demand in HF and CKD.Brilinta/Brilique(ticagrelor)Acute coronary syndromes(ACS)$1,333m,up 1%(2%at CER)Brilinta plus

276、aspirin is currently approved in more than 124 countries for the prevention of atherothrombotic events in adult patients with ACS and in 80 countries for the secondary prevention of CV events among high-risk patients who have experienced a heart attack.Crestor(rosuvastatin calcium)Dyslipidaemia Hype

277、r-cholesterolaemia$1,155m,up 4%(8%at CER)Approved in 91 countries as an adjunct to diet to reduce elevated Total-C,LDL-C,ApoB,non-HDL-C,and triglycerides and to increase HDL-C in adult patients with primary hyperlipidaemia or mixed dyslipidaemia.Seloken/Toprol-XL(metoprolol succinate)Hypertension HF

278、 Angina$606m,down 5%(stable at CER)Approved in 62 countries to treat hypertension,angina,cardiac arrhythmias and post-CV event prophylaxis.Lokelma(sodium zirconium cyclosilicate)Hyperkalaemia(HK)$542m,up 32%(34%at CER)Approved in 56 markets and is market leader by days-of-therapy volume in branded H

279、K market and the number one ranked K+binder across 13 countries.RoxadustatAnaemia of CKD$336m,up 22%(23%at CER)Roxadustat is used to treat adults with symptomatic anaemia associated with CKD.Andexxa/Ondexxya(andexanet alfa)Factor Xa(FXa)inhibitor reversal agent$219m,up 20%(22%at CER)Andexxa holds an

280、 accelerated approval in the US and a conditional approval by the EMA for reversal of the anticoagulant effect of FXa in patients with life-threatening or uncontrolled bleeds.In the third quarter of 2024,following a strategic review of portfolio priorities,the business decision was made to cease pro

281、motional activity for Andexxa.Wainua/Wainzua(eplontersen)Polyneuropathy of hereditary transthyretin-mediated amyloidosis(ATTRv-PN)$85mApproved in six countries,including in the US,for the treatment of adult patients with stage one or two ATTRv-PN.Source:IQVIA.AstraZeneca focuses on specific segments

282、 within this overall therapy area market.Sales for CKD($9.6bn)and CKD-associated anaemia($5.0bn)fall outside the CVRM total market.All sales for CKD-associated anaemia($5.0bn)fall within the CKD market and should not be double counted.Full details are given in the Development Pipeline and Patent Exp

283、iries of Key Marketed Products Supplements on our website, 22AstraZeneca Annual Report&Form 20-F Information 2024Strategic ReportTherapy Area Review|BioPharmaceuticals continuedmortality,cardiovascular outcomes,and deterioration of kidney function that is independent of blood pressure.Balcinrenone/d

284、apagliflozin aims to address the unmet medical need in HF patients with impaired kidney function by delivering the benefits of mineralocorticoid receptor antagonists(MRAs)without hyperkalaemia risk.The Phase III BalanceD-HF trial commenced recruitment.Our ambition is to lead dyslipidaemia care,helpi

285、ng patients to reduce risk of chronic CV disease.Our pipeline includes AZD0780(oPCSK9i)as an adjunct to statins and in combination with other lipid-lowering therapies.Phase II studies of AZD0780 will complete and be presented in 2025.Our relaxin portfolio aims to improve cardiac function by recapitu

286、lating the biology of relaxin,a natural pregnancy hormone,in patients with HF and pulmonary hypertension(PH).AZD3427,currently in Phase IIb trials,is a long-acting peptide analogue of relaxin and one of the first therapies to specifically address group 2 PH,the largest PH population,in HF.AZD5462 is

287、 the first and only small molecule targeting relaxin biology to enter clinical trials,currently in Phase IIb.We are exploring its potential to become a foundational therapy in a broad range of patients with HF.RenalNearly 850 million people worldwide are affected by kidney disease.Our ambition in CK

288、D is to eliminate progression to kidney failure.In 2024,the Kidney Disease Improving Global Outcomes CKD guidelines included use of SGLT2s as a class 1a recommendation for patients with CKD regardless of T2D status,including use in patients with CKD and HF.New modelling analyses(IMPACT CKD,DISCOVER

289、CKD,PaCE CKD)demonstrated the benefits of earlier CKD diagnosis and access to guideline-directed medical therapies for economies,healthcare systems,and quality of life for patients.We are focusing on subpopulations of patients with CKD in our clinical development programme,with unique mechanisms tha

290、t target disease drivers and risk factors that impact disease progression,on top of the proven cardiorenal protection of dapagliflozin.Zibotentan/dapagliflozin has advanced into Phase III ZENITH High Proteinuria for patients with CKD and high proteinuria.The combination is also being developed in li

291、ver cirrhosis and entered Phase II development with the ZEAL trial.Baxdrostat/dapagliflozin has advanced into Phase III BaxDuo Arctic for patients with CKD and hypertension.Balcinrenone/dapagliflozin has advanced into Phase IIb MIRO-CKD for patients with CKD at higher risk of developing hyperkalaemi

292、a.AZD2373,developed in collaboration with Ionis,has the potential to be the first precision medicine in our renal pipeline for treatment of APOL-1 mediated kidney disease(AMKD).Phase I data has demonstrated safety,tolerability and proof of mechanism in healthy participants.MetabolismSixty per cent o

293、f people diagnosed with obesity or as overweight(BMI 27kg/m2)have at least one comorbidity.We continue to build a comprehensive weight management portfolio to deliver durable weight management and to provide organ protection.Three key assets(AZD5004(oral GLP-1RA),AZD6234(LA amylin)and AZD9550(GLP-1/

294、GCG RA)delivered positive Phase I data in 2024.We have entered Phase II trials in T2D(AZD5004 SOLSTICE)and obesity(AZD5004 VISTA and AZD6234 APRICUS studies).A triple mechanism combination therapy(AZD9550+AZD6234)is set to enter Phase II in the first half of 2025.We are also advancing an innovative

295、pipeline in metabolic dysfunction-associated steatohepatitis(MASH)and advanced liver disease to specifically target the main disease drivers.This includes a precision medicine approach with AZD2693(PNPLA3 ASO)in patients with a genetic predisposition to MASH,currently in Phase IIb studies,and AZD238

296、9(small molecule FAP inhibitor)targeting advanced liver fibrosis currently in Phase II studies.In June 2024,following the T2NOW Phase III trial,Farxiga was approved by the FDA to improve glycaemic control in paediatric patients aged 10 years and older with T2D.Healthcare in the communityAstraZeneca

297、is proud to support the Everton in the Community(Everton Football Clubs official charity)NexGen Breathlessness Hub.The Hub enables prompt review of people with chronic breathlessness to establish a diagnosis,such as heart failure or COPD.It serves one of the most deprived UK neighbourhoods,and its c

298、onvenient location in Evertons The Peoples Place embeds rapid,equitable access to essential diagnostics in the community.Over 1,000 people have received lung and heart health checks,25%underwent NT-proBNP testing and AI-assisted echocardiography to assess cardiac function with 3%newly diagnosed with

299、 HF.There is a significant correlation between deprivation levels and HF hospitalisation and survival;providing rapid diagnosis and early treatment could improve long-term outcomes.Corporate GovernanceAdditional InformationFinancial StatementsStrategic Report23AstraZeneca Annual Report&Form 20-F Inf

300、ormation 2024Therapy Area Review|BioPharmaceuticals|Cardiovascular,Renal&Metabolism$29.7bn Asthma$17.1bn COPD$44.9bn Other$91.9bn$91.9bnAnnual worldwide market valueTherapy area world market(MAT Q3-24)Our strategy in R&I Our ambition is to transform care in respiratory and immune-mediated diseases b

301、y moving beyond symptom control to achieve disease modification,remission and,one day,cures for millions of patients worldwide.COPDWe are working to eliminate COPD as a leading cause of death,transforming care through our broad portfolio by:Driving timely diagnosis,optimising therapeutic interventio

302、n and reducing mortality by addressing cardiopulmonary risk.Advancing innovative medicines including next-generation biologics and orals to slow disease progression and reverse the structural damage caused by COPD.AsthmaWe strive to eliminate asthma attacks and achieve clinical remission by:Reinforc

303、ing our anti-inflammatory reliever inhaled portfolio as the backbone of care.Driving towards clinical remission with systemic biologics.Introducing novel oral and inhaled medicines to address patients who are not controlled on SoC inhaled therapy.Other RespiratoryWe are moving beyond asthma and COPD

304、 to address other respiratory diseases with significant unmet medical need,including severe viral lower respiratory tract disease,non-cystic fibrosis bronchiectasis,interstitial lung disease and idiopathic pulmonary fibrosis(IPF).ImmunologyWe aim to disrupt in immunology,redefining treatment paradig

305、ms in areas of high unmet medical need,moving to clinical remission and eventually cure by:Targeting underlying disease drivers in lupus and related diseases to address high unmet medical need at each stage of the patient journey.Exceeding current efficacy expectations in established diseases with s

306、uboptimal treatment outcomes through targeting novel mechanisms and applying precision medicine in diseases such as Crohns disease and rheumatoid arthritis.Accelerating transformative technologies,such as complex biologics and cell therapy,with the goal of moving towards cure.SustainabilityWithin R&

307、I,we are leading the way in reducing the environmental burden of care by driving improvements in patient outcomes as well as transitioning to inhaled respiratory medicines with a propellant that has near-zero GWP.Key marketed productsProductDiseaseTotal RevenueCommentary Symbicort(budesonide/formote

308、rol)Asthma COPD$2,879m,up 22%(25%at CER)Symbicort continued its volume market leadership as the number one inhaled corticosteroid(ICS)/LABA combination globally and had significant growth across Emerging Markets.It is the only branded ICS/LABA approved in mild asthma as an anti-inflammatory reliever

309、 in 47 countries.Fasenra(benralizumab)Severe eosinophilic asthma(SEA)Eosinophilic granulomatosis with polyangiitis(EGPA)$1,689m,up 9%(9%at CER)Approved as an add-on maintenance treatment for SEA in 83 countries including the US,EU,Japan and now China.Also broadened the population in the US and Japan

310、 to patients six years and older.Expanded into immunology with approvals in more than 35 countries including the US,EU and Japan for the treatment of EGPA.Pulmicort(budesonide)AsthmaCOPDCroup$682m,down 4%(1%at CER)Approved in more than 115 countries.Breztri/Trixeo(budesonide/glycopyrrolate/formotero

311、l)COPD$978m,up 44%(46%at CER)Approved in more than 80 countries,including the US,EU,Japan and China.GOLD 2025 emphasises the important role of fixed-dose triple therapy1,particularly for reducing mortality,preventing exacerbations and addressing CV risk.It also highlights more direct pathways for pa

312、tients to get treated with triple therapy.Tezspire(tezepelumab)Severe asthma$684m,up 98%(99%at CER)Approved in more than 60 countries including the US,EU and Japan for the treatment of severe asthma without biomarkers or phenotypic limitations.Saphnelo(anifrolumab)Systemic lupus erythematosus(SLE)$4

313、74m,up 69%(70%at CER)Approved for the treatment of SLE in more than 65 countries,including the US,EU and Japan.First biologic to demonstrate sustained SLE remission in a clinical trial over four years compared to standard therapy;aligned with updated 2023 EULAR recommendations,which focus on remissi

314、on as a treatment goal.Airsupra(albuterol/budesonide)Asthma$66m The only FDA-approved short-acting beta2-agonist(SABA)/ICS anti-inflammatory rescue treatment approved in asthma for the treatment of symptoms and prevention of exacerbations.The anti-inflammatory rescue approach is the preferred treatm

315、ent approach as recommended by the Global Initiative for Asthma.1 Global triple therapy market definition:Breztri,Enerzair,Trelegy,Trimbow.Source:IQVIA.AstraZeneca focuses on specific segments within this overall therapy area market.Full details are given in the Development Pipeline and Patent Expir

316、ies of Key Marketed Products Supplements on our website, Annual Report&Form 20-F Information 2024Strategic ReportTherapy Area Review|BioPharmaceuticals continued2024 review strategy in actionCOPDBreztri remains the fastest-growing triple inhaled therapy within the growing fixed-dose combination trip

317、le class across major markets.Breztri has demonstrated a reduction in mortality that has been recognised in the 2025 Report published by the Global Initiative for Lung Disease(GOLD).In March 2024,we initiated the first Phase III cardiopulmonary outcomes trial in COPD,THARROS,to investigate Breztris

318、potential to improve cardiopulmonary outcomes,including death from respiratory and cardiac causes.In the fourth quarter of 2024,we submitted regulatory filings in the EU,UK and China to support the transition of Breztri(marketed as Trixeo in Europe)as the first medicine in our inhaled portfolio to u

319、se our next-generation propellant with near-zero GWP.We remain on track to transition our portfolio of inhaled respiratory medicines delivered by pressurised metered-dose inhalers(pMDIs)by 2030,as part of our Ambition Zero Carbon strategy.While pMDIs contribute less than 0.04%of GHG emissions,AstraZ

320、eneca is committed to significantly reducing this burden.We have a robust late-stage biologics programme in COPD:tozorakimab(Phase III LUNA programme),which has a unique dual mechanism of action targeting IL-33,plus indication expansion opportunities with Fasenra(Phase III RESOLUTE trial)and Tezspir

321、e(Phase III trial planned).Our innovative early pipeline in COPD is aimed at reaching patients who will not have access to biologics,but no longer respond to inhaled therapy.AZD6793 is an oral small molecule IRAK4 inhibitor in Phase I development targeting key COPD disease drivers triggered by bacte

322、rial and viral infections,smoke and other environmental factors.AsthmaAirsupra has had strong uptake in the US as the first and only FDA-approved anti-inflammatory rescue therapy that treats symptoms and prevents exacerbations.In October 2024,we announced that Airsupra demonstrated a statistically s

323、ignificant and clinically meaningful reduction in the risk of a severe exacerbation in patients with intermittent or mild or persistent asthma in the BATURA Phase III trial.Symbicort maintained its position as the leading inhaled corticosteroid(ICS)/long acting beta2-agonist(LABA)globally by volume

324、and value.Performance has been driven by strong growth in Emerging Markets,and resilient performance in the US offset by generic erosion in the EU and Japan.Tezspire continues gaining market share,achieving labels for a broad population of severe asthma patients,and securing reimbursement globally.W

325、e also announced positive high-level results from the Phase III WAYPOINT trial studying Tezspire for the treatment of chronic rhinosinusitis with nasal polyps.In 2024,US and Japan regulatory authorities approved the paediatric indication for Fasenra for SEA,in patients as young as six years old.In A

326、ugust 2024,we announced the approval of Fasenra for SEA in China in people 12 years of age and older based on positive results from the MIRACLE Phase III trial.Two Phase III pivotal trials,KALOS and LOGOS are investigating Breztri in asthma.Our early pipeline is exploring innovative compounds includ

327、ing new modalities,aimed at targeting key disease mechanisms:AZD8630,an inhaled fragment antibody(inhaled biologic)in Phase II in co-development with Amgen,targets thymic stromal lymphopoietin(TSLP).Atuliflapon,an oral 5-lipoxygenase-activating protein(FLAP)inhibitor in Phase IIa,could offer an alte

328、rnative for uncontrolled patients before systemic biologics.AZD4604,an inhaled JAK1 inhibitor in Phase IIa has the potential to block the effects of T2-high pro-inflammatory pathways(IL4/13,TSLP)and T2-lower pathways(IL6,interferon).Other RespiratoryThe TILIA Phase III trial of tozorakimab in severe

329、 viral lower respiratory tract disease is ongoing.AZD8965,an oral small molecule arginase inhibitor,in Phase I for IPF has the potential to stop disease progression by blocking collagen synthesis,which is deposited in the lungs of patients with IPF.ImmunologySaphnelo continues its rapid growth.At th

330、e European Lupus Meeting 2024,we announced results from a post-hoc analysis of the Phase III TULIP programme in SLE that showed 30%of patients treated with Saphnelo achieved remission using the Definition of Remission in SLE(DORIS)criteria.Phase III trials are ongoing exploring Saphnelo for SLE in C

331、hina as well as globally in lupus nephritis,cutaneous lupus erythematosus,idiopathic inflammatory myopathies,systemic sclerosis,and in SLE for subcutaneous delivery.For more information on:pMDI inhalers,Scope 1 and 2 Decarbonisation levers,Scope 3 Decarbonisation levers and Transition risk and oppor

332、tunities,see Climate Change from page 53.Fasenra is now approved for the treatment of EGPA in more than 35 countries including the US,EU and Japan,based on positive results from the MANDARA Phase III trial.Tezspire is also being investigated in eosinophilic oesophagitis,a chronic inflammatory diseas

333、e of the gastrointestinal tract.Compounds in early-stage clinical development include three potential first-in-class medicines:AZD0120,a CD19xBCMA biCAR-T therapy in Phase I that may lead to a complete immune reset by targeting both B-cells and plasma cells in SLE patients.AZD7798,a CCR9-depleting mAb in Phase II.CCR9 is the main chemokine receptor for trafficking lymphocytes to the small intestin